Overview of Cylider

Quick Facts

Property	Description
Active ingredient	Cycloserine (D-cycloserine)
Form	Oral Capsule
Pharmacological class	Antibiotic / Antitubercular Agent
General purpose	Specialized treatment of resistant bacterial infections
Origin	Derived from Streptomyces bacteria

What Type of Medicine is Cylider?

Cylider is an antimicrobial pharmaceutical preparation that belongs to the class of antibiotics, specifically designated as a second-line antitubercular agent. This classification means its primary role is fighting specific, severe bacterial infections, particularly those caused by the Mycobacterium tuberculosis complex. The active core ingredient is cycloserine, also known as D-cycloserine, which defines the drug's action and therapeutic category. As an antibiotic active against mycobacteria, cycloserine is utilized when standard first-line therapies are ineffective. Cylider is typically reserved as a second-line agent for specialized use when initial, standard treatments prove ineffective due to drug resistance, serving as a critical defense in complex conditions.

Cylider Composition and Form

Cylider is supplied as an oral medication in a capsule dosage form, containing cycloserine as a single, active ingredient. The substance cycloserine is chemically defined as a derived compound, having been isolated from cultures of certain strains of the Streptomyces bacterium, confirming that its structure originates from a natural biological source. Being a single-ingredient product administered via the oral route, it provides a straightforward method of delivery. The essential function of cycloserine is unique among antibiotics, as it disrupts the construction of the bacterial cell's rigid, protective outer wall by targeting fundamental precursors, an action known generally as the inhibition of bacterial cell wall synthesis.

Why is Cylider Used in Specialized Therapy?

The general purpose of Cylider is to compromise the structural integrity of persistent bacteria, making it a crucial tool against difficult-to-treat and drug-resistant infections. By precisely targeting the formation of the cell wall structure, Cycloserine acts to halt the growth and multiplication of the organism. This effect is described as either bacteriostatic (stopping growth) or bactericidal (killing the bacteria), depending on its local concentration and the susceptibility of the target strain. Its mechanism, which involves mimicking a core bacterial building block (D-alanine), provides a high degree of specificity. This targeting mechanism is applied in treating resistant forms of the target infection, allowing for therapeutic intervention in challenging cases. As a second-line agent, its inclusion in a specialized regimen is key to managing highly resistant bacterial conditions.

What side effects are possible with Cylider?

Cylider's safety profile, as documented in regulatory sources, is characterized by its potential impact on the nervous system (neurotoxicity) and its association with the drug's blood concentration. Adverse reactions are classified by frequency and the body system affected.

Documented Adverse Reactions and Safety Profile

System-Organ Class	Examples of Officially Listed Effects
Nervous System	Convulsions (Seizures), Drowsiness, Headache, Tremor, Paresis, Dysarthria, Visual impairment.
Psychiatric	Psychoses, Depression, Severe Anxiety, Suicidal Ideation, Confusion.
Cardiac	Sudden development of Congestive Heart Failure.
Gastrointestinal	Nausea, Vomiting, Diarrhea, Abdominal pain.
Hepatobiliary	Elevated serum transaminases (Liver enzymes).

Regulatory documents specify that the nervous system symptoms are often dose-related, meaning they appear more frequently when the blood levels of the medicine are high or if a patient has impaired renal clearance. These central nervous system effects are reported to occur within the first two weeks of therapy in a significant percentage of patients receiving higher dosages.

Serious adverse reactions that have been documented include convulsions, psychoses, and congestive heart failure.

Safety Restrictions and Special Populations

Safety constraints established in official labeling include contraindications for individuals with a history of epilepsy, severe anxiety, depression, or psychosis. The medicine is also contraindicated for those with severe renal insufficiency, as its primary route of clearance is through the kidneys. Caution is advised for older adults, who may have age-related reductions in renal function. For pediatric patients, safety and effectiveness have not been formally established by the FDA.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Cycloserine (Cylider) overdose is characterized by severe Central Nervous System (CNS) toxicity. Documented clinical manifestations range from disorientation, headache, tremor, and somnolence to serious events including psychosis, convulsions, and coma. Acute toxicity has been specifically reported following the ingestion of more than 1 gram by an adult. Toxicity is closely associated with excessive drug concentrations in the blood, often exceeding 30 mu g/ mL, and inadequate renal clearance.

Mandated Emergency Action

Immediate medical attention is required for any signs of life-threatening toxicity, such as severe seizures, loss of consciousness, or the sudden onset of congestive heart failure. Furthermore, official guidelines mandate the immediate reporting of any observed undue depression or personality change to a healthcare professional.

Supportive Management Measures

Since no specific antidote is known, the management protocol is defined as symptomatic and supportive. Procedures described in official labeling include protecting the patient's airway, supporting circulation, and using measures such as activated charcoal for gastrointestinal decontamination. Meticulous monitoring of vital signs, blood gases, and serum electrolytes is required. The risk of convulsions is specifically noted as increased in chronic alcoholics.

Therapeutic Uses of Cylider

What Cylider Treats: Main Uses and Benefits

Cylider is a specialized agent applied in treating active pulmonary and extrapulmonary tuberculosis (TB) in situations where the infection is confirmed to be resistant to, or if the patient cannot tolerate, primary medications. Its therapeutic scope is relevant for managing conditions involving multidrug-resistant (MDR) or extensively drug-resistant (XDR) strains, which are conditions characterized by heightened physiological stress and persistent symptomatic discomfort.

Its use plays a role in managing the infection, which contributes to easing symptom clusters related to systemic imbalance, such as chronic fever, night sweats, and unintentional weight loss. The medicine is generally used as a second-line agent when initial, standard treatment protocols are considered inadequate due to resistance or intolerance. The agent is also indicated for certain acute Urinary Tract Infections (UTIs) caused by susceptible organisms.

Quick Fact: Context for Resistant Infections

Property	Description
Primary Focus	Multidrug-Resistant Tuberculosis (MDR-TB)
Symptoms Addressed	Chronic fever, night sweats, and systemic distress
Clinical Context	Used as a second-line agent in combination therapy
Key Patient Benefit	Contributes to easing the overall symptom load during periods of infection management

Regulatory References

DailyMed Label from the National Library of Medicine (NIH)

Eligibility and Restrictions for Use

Cylider (cycloserine) is a specialized antibiotic whose eligibility is strictly defined by regulatory documents, emphasizing neurological status and kidney function.

Populations for Whom Use is Contraindicated

Use is prohibited (contraindicated) in patients with specific preexisting conditions as documented by official labels:

Neurological/Psychiatric Conditions: A history of epilepsy or other convulsive disorders, or existing severe mental depression, psychosis, or severe anxiety.
Renal Function: The presence of severe renal insufficiency.
Substance Use: Excessive concurrent use of alcohol.
Hypersensitivity: Known allergy to cycloserine or its inactive ingredients.

Restricted and Conditional Eligibility

Eligibility is limited or conditional for the following populations:

Non-Severe Renal Impairment: Patients with reduced kidney function are eligible only with close monitoring of drug blood levels and necessary dosage adjustments.
Pregnancy: Use is restricted to situations where the medicine is clearly needed and when the potential benefit outweighs the potential risk.
Breastfeeding: Cycloserine passes into breast milk. While some regulators state it is not a reason to discontinue breastfeeding, the infant must be monitored for adverse effects.
Pediatric Use: Safety and effectiveness have not been established in all pediatric patients according to some regulatory documents, though its use in children is established practice for drug-resistant conditions.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Cylider (Cycloserine) establishes patterns for combinations that alter drug exposure or heighten effects on the central nervous system (CNS).

Contraindicated Combinations and Substances

The most stringent restriction is the formal contraindication against excessive concurrent use of Alcohol (Ethanol), a requirement established in regulatory labeling due to the substantial risk of amplified CNS effects, including convulsions and seizures. This specific risk is explicitly noted to be greater in chronic alcoholic populations. Separately, the administration of Cylider with a high-fat meal is documented to negatively affect the drug's absorption.

Pharmacokinetic and Pharmacodynamic Interactions

Key drug-drug interactions involve antitubercular agents and anticonvulsants. Co-administration with Isoniazid decreases Cylider's metabolism, resulting in increased Cylider plasma concentrations and a resulting enhancement of CNS effects. Cylider is also documented to exert a pharmacokinetic interaction by inhibiting the hepatic metabolism of Phenytoin, leading to increased Phenytoin plasma exposure.

Additionally, the drug's profile includes pharmacodynamic potentiation of neurotoxicity when combined with other neurotoxic agents, such as Ethionamide and Delamanid. To mitigate the increased risk of neurotoxicity stemming from these documented interactions, regulatory documents officially recommend the concomitant administration of Pyridoxine (Vitamin B6).

Mechanism of Action

Molecular Mimicry and Enzymatic Blockade

Cylider (Cycloserine) acts as an antimicrobial agent by interfering with the synthesis of the bacterial cell wall, a unique structural process absent in human cells.

The mechanism begins where Cycloserine acts as a structural analogue of the bacterial amino acid D-alanine. This mimicry allows the compound to competitively bind to and inactivate two critical bacterial enzymes: D-Alanine Racemase and D-Alanine:D-Alanine Ligase. This blockade halts the necessary formation of the D-Ala-D-Ala dipeptide precursor, thereby resulting in the interruption of the initial steps of the cell wall construction cascade.

Pathway Disruption and Structural Failure

The cessation of these vital precursors causes the resulting peptidoglycan layer—the rigid mesh structure that forms the bacterial cell wall—to be assembled defectively. This structural defect compromises the physical integrity of the bacterial organism, as the weakened wall cannot withstand the naturally high internal osmotic pressure. The result is the rupture and death (lysis) of actively growing bacteria, producing a bacteriostatic or bactericidal consequence on the target organism.

Constraints of Activity

The compound's action is inherently dependent on the active replication and growth of the bacteria, as its mechanism targets the ongoing synthesis of new cell wall components. Consequently, the effect of the compound is weaker against bacteria that are in a dormant, non-replicating state, defining a key constraint in the full expression of the mechanism's action.

Dosage and Administration Information

Cylider (glycopyrrolate injection) is an injectable prescription medicine for administration by a healthcare professional, primarily via intramuscular (IM) or intravenous (IV) injection. It is supplied as a ready-to-use solution that may be administered without dilution, but should not be mixed with other fluids in the syringe for IV push.

Official Dosing and Administration

The dosage and timing are highly dependent on the medical context, whether used in anesthesia or as adjunctive therapy for peptic ulcer in adults. For preanesthetic medication, the IM dose is typically given 30 to 60 minutes prior to the anticipated time of anesthesia induction.

Clinical Use	Administration Route and Dose (Adults)
Preanesthetic Medication	0.004 mg/kg IM, once.
Intraoperative Medication	Single doses of 0.1 mg IV, repeated as needed at 2 to 3-minute intervals.
Reversal of Neuromuscular Blockade	0.2 mg IV for each 1 mg of neostigmine or 5 mg of pyridostigmine.
Peptic Ulcer (Adults only)	0.1 mg to 0.2 mg IV or IM at 4-hour intervals, up to four times daily.

Age-Specific Rules

For pediatric patients, use for anesthesia follows similar weight-based rules, such as 0.004 mg/kg IM for preanesthetic use, though children under two years old may require up to 0.009 mg/kg IM. The drug is not indicated for the treatment of peptic ulcer in pediatric patients. In the event of reversal of neuromuscular blockade, Cylider and the cholinergic agent (e.g., neostigmine) may be administered simultaneously and mixed in the same syringe to help minimize cardiac effects. This product is intended for single-dose only and any unused portion must be discarded.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cylider

Evidence for Use in Drug-Resistant Tuberculosis (MDR/XDR-TB)

Research was conducted on Cylider's role within complex combination therapies used to address serious bacterial infections, particularly multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). The research landscape for this indication mainly involves Systematic Reviews and Meta-analyses that combine data from many sources, alongside Observational Cohort Studies where patient outcomes are monitored over defined time intervals. This approach is relevant in resistant diseases where large, randomized trials are difficult to conduct.

Researchers have examined outcomes related to infection control, such as sputum culture conversion rates, which measure when the bacteria are no longer detectable. Studies also monitored the overall treatment success rate, which is a composite measure defined by regulators to track the percentage of patients achieving a regulatory definition of cure or treatment completion. Research describes patterns observed related to these measured changes in the observed populations.

Evidence for Use in Specific Urinary Tract Infections (UTIs)

The primary evidence evaluating this regulated use was observed in older clinical reports and non-randomized therapeutic trials conducted many decades ago. These studies focused on short-term outcomes, such as the clearance of the target organism from the urine and the observed evolution of acute symptoms. The findings indicate that the research at that time examined the drug's short-term effects against certain pathogens.

Documented Research Gaps and Uncertainties

The research base includes several recognized limitations. Comparative evidence is lacking from modern large-scale Randomized Controlled Trials (RCTs) against contemporary standard-of-care regimens. The challenge of measuring effects is another gap; because Cylider was evaluated in combination therapy, researchers cannot easily isolate and measure the specific effect of the single medicine. Furthermore, evidence quality varies across studies, and the heterogeneity in treatment regimens, patient populations, and resistance patterns means that the findings were mixed or inconsistent in some areas, leading to a recognized level of uncertainty in certain subgroup findings.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cylider (FAQ)

Q: Are there any common foods or drinks that interact with Cylider?

A: Regulatory documents provide two specific warnings related to intake. The concurrent use of alcohol is formally contraindicated, a regulatory classification that indicates a substantial risk of increased central nervous system (CNS) effects. Regarding food, official product information indicates that taking Cylider with a high-fat meal may affect the drug’s absorption into the body.

Q: Are there any known interactions between Cylider and common vitamins or supplements?

A: Official regulatory warnings document that the concomitant administration of Pyridoxine (Vitamin B6) is a strategy to help minimize the neurotoxic effects sometimes associated with Cylider. Additionally, official information notes that the drug may increase the body's dietary requirements for both folic acid and Vitamin B12.

Q: Are the side effects of Cylider usually temporary?

A: Official product information does not provide a general statement on the typical duration or resolution of all side effects. However, it is noted that the neurotoxic (nervous system) side effects are generally dose-related and are reported to occur within the first two weeks of therapy. These effects are also more likely if the drug's blood levels are high or if a patient has impaired kidney function.

Q: Why is Cylider sometimes prescribed instead of other options?

A: Cylider is classified by regulatory and public health bodies as a second-line antitubercular agent. Its use is specifically reserved for complex treatment regimens against drug-resistant strains of M. tuberculosis when first-line drugs cannot be used or have proven ineffective. The mechanism is noted to be highly specific, which supports its classification as a specialized agent for these specific resistant infections.

Q: Can Cylider cause changes in mood or behavior?

A: Yes, official safety documents list significant psychiatric effects, which are related to the drug's known central nervous system (CNS) toxicity. Officially listed effects include psychoses, depression, severe anxiety, suicidal ideation, and confusion. These are generally tied to the concentration of the drug in the blood.

Q: How long is Cylider usually taken for?

A: When used for the treatment of active drug-resistant tuberculosis, regulatory-based guidelines suggest that Cylider is administered as part of a combination regimen for an extended period. This duration is often noted to be between 18 and 24 months.

Q: Is Cylider available over the counter, or does it require a prescription?

A: Cylider (Cycloserine) is categorized as a prescription-only (Rx-only) medicine. It is not available for retail purchase outside of a prescription.

Q: Is Cylider considered a controlled substance?

A: Official drug classifications categorize Cylider as an antibiotic/antitubercular agent. The drug is not classified as a scheduled controlled substance under the U.S. Controlled Substances Act.

Q: Can Cylider be used for conditions other than those listed in the official documents?

A: Official regulatory documents specify the conditions for which Cylider has been approved: the treatment of specific drug-resistant tuberculosis and, historically, certain urinary tract infections (UTIs). The prescribing information only defines the drug’s regulated uses and does not contain information on use for other conditions.

Q: What are the potential long-term effects described in research for Cylider?

A: Official warnings describe the risk of potential chronic toxicity which is related to the dose and blood concentration of the medicine. This documented risk profile is the basis for the established practice of frequent professional monitoring of blood levels and kidney function in patients who are on a long-term treatment regimen.

Q: Why do some people report feeling tired after taking Cylider?

A: Drowsiness (somnolence) is an officially listed adverse effect of Cylider in the product labeling. This effect is part of the drug's known central nervous system (CNS) toxicity profile.

Q: Can Cylider be crushed or split?

A: Cylider is supplied as an oral capsule dosage form. The official labeling does not contain instructions for crushing, splitting, or otherwise altering the capsule dosage form.

Q: How long does Cylider stay in your system?

A: Pharmacokinetic data indicates the drug is cleared through the kidneys. The drug's elimination half-life—the time it takes for half the drug to leave the body—is approximately 10 hours in individuals with normal kidney function.

Q: What is the half-life of Cylider?

A: The elimination half-life of Cylider (Cycloserine) is reported to be approximately 10 hours in patients who have normal kidney function. This is a measure of the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Does taking Cylider at a specific time of day matter?

A: The official dosage is typically once or twice daily. The label does not mandate a specific time of day; however, it notes that a high-fat meal affects the drug's absorption.

Q: Has Cylider been studied in children or adolescents?

A: While the FDA label notes that safety and effectiveness have not been established in children, major official public health guidelines establish its use, dosage, and monitoring for drug-resistant tuberculosis in infants, children, and adolescents. This use is based on established clinical practice and pharmacokinetic data.

Q: Are there common skin reactions associated with Cylider use?

A: Yes, official adverse event information lists several skin reactions. These include allergic dermatitis, a skin inflammation, and a rash known as lichenoid eruption. More rarely, severe reactions like Stevens-Johnson syndrome have also been officially documented.

Q: Do older adults react differently to Cylider than younger adults?

A: Caution is specifically advised for older adult patients in the official warnings. This is because age-related reductions in renal (kidney) function can lead to the medicine accumulating in the body, which increases the risk of central nervous system (CNS) toxicity.

Q: Is Cylider associated with any vision or hearing changes?

A: The official adverse reaction list includes visual impairment and disorientation as effects related to the central nervous system. However, hearing changes (ototoxicity) are not listed in the drug's primary adverse reaction profile.

Q: Is Cylider part of a combination therapy?

A: Yes. Regulatory guidelines state that Cylider is not indicated for use as a single agent for its primary regulated purpose. It is administered in conjunction with other effective chemotherapy as part of a multi-drug regimen for the treatment of tuberculosis.

How should Cylider be stored and disposed of?

How to Store and Dispose of Cylider?

The storage and disposal of Cylider (cycloserine capsules) must follow strict regulatory guidelines to maintain product stability and protect the environment.

Storage Requirements

Cylider must be stored at room temperature, generally defined as below 25 C. It is mandatory to keep from freezing and protect the capsules away from excess heat, moisture, and direct light. The medication should be kept in the original container, which must be maintained tightly closed to prevent moisture ingress. For safety, the product must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Cylider should not be thrown away via household waste or wastewater. Consult your pharmacist or local waste disposal company for instructions on proper disposal, which must be done in accordance with local requirements.

Cylider